Stocklytics Platform
Asset logo for symbol RGEN
Asset logo for symbol RGEN


Key Stats
Prev. Close$123.81
Next Earnings Date-
Dividend Yield %-
Day Range122.89
52 Week Range110.45
Payout Ratio-
Industry average yield2.88%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_up1.19%
US Marketarrow_drop_up0.66%
RGEN / Market
RGEN exceeded the US Market which returned 0.66% over the last twenty four hours.
RGEN / Healthcare Sector
RGEN exceeded the US Healthcare sector which returned 1.19% over the last twenty four hours.

Repligen (RGEN) Statistics

Repligen Corp (RGEN) is a bioprocessing company that provides products and services to improve the way biological drugs are made. As of September 30, 2021, the stock had a market capitalization of $17.34 billion. The company's stock has been performing well compared to the sector, with a year-to-date return of 77.6% as of November 17, 2021. This is significantly higher than the sector's return of 18.5%. Repligen Corp has been able to generate strong revenue per share, with the latest reported figure being $1.19. This indicates that the company is able to generate a decent amount of revenue for each outstanding share of stock.

The enterprise to EBITDA ratio, which measures the company's ability to generate income from its operations, was 137.96 as of September 30, 2021. This indicates that Repligen Corp is generating significant earnings before interest, taxes, depreciation, and amortization. The company has also maintained a healthy profit margin, with the latest reported figure being 35.4%. This indicates that Repligen Corp is able to generate a good amount of profit for each dollar of revenue. On the debt front, the company has managed to maintain a relatively low level of total debt, with the latest reported figure being $69.19 million. This indicates that Repligen Corp has a solid financial position and is not overly burdened by debt. The company has also recorded a strong gross profit, with the latest reported figure being $92.2 million. This indicates that Repligen Corp is able to generate a substantial amount of profit after deducting the cost of goods sold.

add Repligen to watchlist

Keep an eye on Repligen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has Repligen (RGEN) stock's performance compared to its sector and the market over the past year?

Over the past year, Repligen (RGEN) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.71%, Repligen has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 51.15%, it has fallen short of the market average. This comparison highlights Repligen's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of Repligen (RGEN) stock?

The PE (Price to Earnings) ratio of Repligen (RGEN) is currently 491.41. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

What is the EPS of Repligen (RGEN) stock?

The Earnings Per Share (EPS) for Repligen (RGEN), calculated on a diluted basis, is $0.27. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of Repligen (RGEN) stock?

The operating margin for Repligen (RGEN) is 1.34%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of Repligen (RGEN) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Repligen (RGEN) is $92.14M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does Repligen (RGEN) have?

Repligen (RGEN) has a total debt of $737.73M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$42.89M.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level